Francis J Giles

13PUBLICATIONS
104CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Medical molecular engineering of nucleic acids and proteinsBiologically active moleculesMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Apr 14, 2026
Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial.

Devalingam Mahalingam, Rachna T Shroff, Benedito A Carneiro

|Nov 20, 2023
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies.

Benedito A Carneiro, Ludimila Cavalcante, Devalingam Mahalingam

|Oct 14, 2023
SLAM Modification as an Immune-Modulatory Therapeutic Approach in Cancer.

Alireza Tojjari, Francis J Giles, Maysa Vilbert

|Jul 14, 2023
GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer.

Kelsey E Huntington, Anna D Louie, Praveen R Srinivasan

|Nov 14, 2022
Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation.

Queralt Serra-Camprubí, Helena Verdaguer, Winona Oliveros

|Mar 11, 2021
A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma.

Priya Kumthekar, Caroline H Ko, Tatjana Paunesku

Pageof 3

Frequent Collaborators

3 joint publications

Benedito A Carneiro

2 joint publications

Devalingam Mahalingam

2 joint publications

Vaibhav Sahai

2 joint publications

Ludimila Cavalcante